Inner Cosmos

Founders and Team

Inner Cosmos was founded in 2016 by a team of entrepreneurs and neurosurgeons, including CEO Meron Gribetz, to develop a minimally invasive brain-computer interface for psychiatric conditions [Crunchbase]. The company is headquartered in Portola Valley, California [Crunchbase].

How the Company Got Here

Inner Cosmos was founded in 2016 by a team of entrepreneurs and neurosurgeons, including CEO Meron Gribetz, to develop a minimally invasive brain-computer interface for psychiatric conditions [Crunchbase]. The company is headquartered in Portola Valley, California, a location that places it within the broader San Francisco Bay Area's life sciences and venture capital ecosystem [Crunchbase].

Key milestones have centered on regulatory progress and early clinical validation. The company secured a $10 million seed round in March 2022, led by Lool Ventures [citybiz, 2022-03-30]. A pivotal step was the subsequent approval of an FDA Investigational Device Exemption, clearing the company to begin its first human trial for depression [Neurotech Center, ~2024-2025]. In May 2025, Inner Cosmos reported interim outcomes from its ongoing Early Feasibility Study, citing symptom improvements in its first two patients [Inner Cosmos, May 2025]. The company announced the completion of that FDA Early Feasibility Study in November 2025 [Inner Cosmos, Nov 2025].

Data Accuracy: YELLOW -- Core facts (founding date, HQ, seed round) are confirmed by multiple sources; regulatory and clinical milestones are reported by the company and vertical press but lack independent corroboration.

Product and Technology

The core innovation is a hardware implant designed to treat major depressive disorder through targeted stimulation, a departure from both pharmaceutical and more invasive neuromodulation approaches. The company's "Digital Pill" is a fingernail-sized brain-computer interface (BCI) placed under the skin on the skull, delivering precise micro-stimulations to specific brain networks without penetrating the brain tissue [Neurotech Center, ~2024-2025]. This minimally invasive profile is a key technical differentiator, positioning it between non-invasive therapies like transcranial magnetic stimulation (TMS) and fully invasive deep brain stimulation (DBS). The product's intended mechanism, described by CEO Meron Gribetz as building a "cochlear implant for depression," suggests a focus on chronic, long-term modulation of neural circuits associated with mood regulation [Neurotech Center, ~2024-2025].

The system's development is anchored by its regulatory progress. The company has secured an FDA Investigational Device Exemption to conduct a human trial for depression, the first such approval for a depression BCI in two decades [Neurotech Center, ~2024-2025] [Dealroom.co]. Interim data from this ongoing Early Feasibility Study has been released by the company. In a May 2025 update, Inner Cosmos reported that its first patient achieved a 41% improvement in depressive symptoms from baseline, which it characterized as a 27% gain over that patient's best prior response to TMS [Inner Cosmos, May 2025]. A second patient was reported in November 2025 to have achieved an 83% improvement over a 17-month period [Inner Cosmos, Nov 2025]. The company announced the completion of this FDA Early Feasibility Study in late 2025 [Inner Cosmos, Nov 2025].

Data Accuracy: YELLOW -- Product claims and clinical outcomes are sourced primarily from the company's own communications and niche industry press. The FDA trial status is reported but not independently verified by regulatory documents.

Where the Demand Sits

The market for a new, targeted intervention in major depressive disorder is driven by the persistent failure of existing treatments for a significant portion of the patient population. The most relevant analog is the global market for treatment-resistant depression. A 2022 report from Grand View Research estimated the global treatment-resistant depression market size at $1.3 billion, projecting a compound annual growth rate of 3.5% through 2030 [Grand View Research, 2022]. The World Health Organization has consistently identified depression as a leading cause of disability worldwide [WHO].

Key demand drivers include high non-response rates to first-line antidepressants, procedure limitations of ECT and TMS, and access barriers to novel pharmaceuticals.

Metric	Value
Treatment-Resistant Depression (Global)	$1.3B
Neuromodulation Devices (Global)	$6.5B

Data Accuracy: YELLOW -- Market sizing relies on analogous third-party reports; company-specific TAM/SAM not publicly disclosed.

Competitive Landscape

Inner Cosmos is positioned as a first-mover in a nascent but highly capital-intensive segment: a minimally invasive, skull-mounted brain-computer interface (BCI) specifically for psychiatric indications, a path that avoids the direct brain penetration of more invasive neural recording systems [Bloomberg, 2022].

Data Accuracy: YELLOW -- Competitive landscape is based on analyst assessment of the neuromodulation sector.

Opportunity

If Inner Cosmos can successfully commercialize a safe, effective, and minimally invasive brain implant for depression, it would establish a new standard of care in a multi-billion dollar treatment-resistant patient population. The company's path to this outcome rests on its early FDA regulatory progress and its reported patient outcomes. Inner Cosmos has secured an FDA Investigational Device Exemption for a human trial [Neurotech Center, ~2024-2025]. Published interim data shows Patient 1 achieving a 41% improvement in depressive symptoms from baseline, and Patient 2 showing an 83% improvement over 17 months [Inner Cosmos, May 2025 & Nov 2025].

Data Accuracy: YELLOW -- Key opportunity components (regulatory status, early data) are cited from company sources and niche trade publications; market comparables and expansion logic are analyst inferences.

Sources

1. [Neurotech Center, ~2024-2025] Inner Cosmos Raises $10 Million To Treat Depression With BCI Implant | https://www.neurotechcenter.org/media-pr/forbes-magazine/inner-cosmos-raises-10-million-treat-depression-bci-implant
2. [Dealroom.co] Inner Cosmos company information funding investors | https://app.dealroom.co/companies/inner_cosmos
3. [MassDevice, pre-2026] Inner Cosmos shares data for psychiatric BCI tech | https://www.massdevice.com/inner-cosmos-data-psychiatric-bci-tech/
4. [Inner Cosmos] Inner Cosmos Home Page | https://innercosmos.ai/
5. [Crunchbase] Inner Cosmos Crunchbase Company Profile Funding | https://www.crunchbase.com/organization/inner-cosmos
6. [Bloomberg, 2022] Inner Cosmos Makes Brain-Computer Interface to Rival Elon Musk’s Neuralink | https://www.bloomberg.com/news/articles/2022-03-30/inner-cosmos-makes-bci-to-rival-neuralink-elon-musk
7. [citybiz, 2022-03-30] Inner Cosmos raises $10M seed round led by Lool Ventures | https://citybiz.co/article/inner-cosmos-raises-10m-seed-round-led-by-lool-ventures/
8. [Inner Cosmos, May 2025] Clinical Study Update | Q2 2025 | https://innercosmos.ai/2025/05/13/clinical-study-update-q2-2025/
9. [Inner Cosmos, Nov 2025] Clinical Trial Update | FDA Early Feasibility Study Completion | https://innercosmos.ai/2025/11/26/clinical-trial-update-fda-early-feasibility-study-completion/
10. [Life Science Intelligence, ~2023] Meron Gribetz - Inner Cosmos, Private Partnering Interview at LSI USA '23 | https://www.lifesciencemarketresearch.com/videos/meron-gribetz-inner-cosmos-private-partnering-interview-at-lsi-usa-23
11. [YouTube, 2025] Bullpen KOL Interview | Meron Gribetz | JPM Week 2025 | https://www.youtube.com/watch?v=oQDd_ppiZh0
12. [Grand View Research, 2022] Treatment Resistant Depression Market Size Report, 2022-2030 | https://www.grandviewresearch.com/industry-analysis/treatment-resistant-depression-market
13. [Fortune Business Insights, 2023] Neuromodulation Devices Market Size, Share & Industry Analysis, 2023-2030 | https://www.fortunebusinessinsights.com/neuromodulation-devices-market-102085